NINLARO is indicated: for the treatment of adult patients with multiple myeloma who have received at least one prior therapy, in combination with lenalidomide and dexamethasone; for maintenance therapy in adult patients with multiple myeloma following autologous stem cell transplantation; for maintenance therapy in adult patients with multiple myeloma not treated with stem cell transplantation.